NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
SN BioScience
Jiangsu Hansoh Pharmaceutical Co., Ltd.
US Oncology Research
Gilead Sciences
Sanofi
Pfizer
Wellstat Therapeutics